Archives
-
Axolotl Limb Regeneration and ERK Positional Memory
2026-10-08
Trostle et al. use spatial transcriptomics and the SpatialFlux analysis package to show that anterior/posterior gene expression is asymmetrically distributed along the proximal/distal axis of axolotl limbs. Their findings support an ERK–CYP26B1 signaling connection between tissue asymmetry and positional identity, while also identifying a related boundary in fetal human limbs.
-
Birinapant (TL32711) in Apoptosis Research
2026-10-08
Birinapant is a SMAC mimetic IAP antagonist investigated as a mechanistic tool for studying apoptotic resistance. The available evidence supports a biologically plausible connection between IAP signaling and the MDM1–p53 pathway in colorectal cancer, but the supplied study does not directly test Birinapant, so any biomarker-guided application remains a hypothesis rather than a published conclusion.
-
PP 1 in Cancer and Immunology Research
2026-10-07
PP 1 is a research small molecule used to interrogate Src-family kinase signaling, with reported activity toward Lck, Fyn, and Lyn. This overview distinguishes supplier-reported pharmacology from peer-reviewed evidence, compares Src-pathway questions with findings from Keller et al. on EDI3 in HER2-therapy-resistant breast cancer, and explains key limitations for cancer, immunology, and translational interpretation.
-
G-15 and GPR30: From Signaling to Pain Biology
2026-10-07
GPR30 is emerging as a mechanistic bridge between estrogen-sensitive signaling, spinal circuit plasticity, and neuropathic pain. This thought-leadership analysis examines how G-15, a G protein-coupled estrogen receptor antagonist, can support receptor-focused translational research while emphasizing evidence boundaries, orthogonal validation, and the distinction between preclinical target biology and clinical opportunity.
-
WEHI-539 and BCL-XL Dependence in Glioblastoma
2026-10-06
This source-grounded overview examines WEHI-539 as a selective BCL-XL inhibitor and places it in the context of mitochondrial apoptosis research. It reviews reported findings from a glioblastoma study linking MCL-1 enhancer activity with resistance to BCL-2 family inhibition, compares biochemical, cellular and in vivo evidence, and outlines limitations affecting interpretation and applicability.
-
Neuroligin 1, D2-MSNs, and Repetitive Behavior
2026-10-06
The reference study identifies a cell-type-specific mechanism linking Neuroligin 1 loss in striatal dopamine receptor D2-expressing medium spiny neurons to excessive self-grooming and digging in mice. By combining behavioral analysis, neuronal activity manipulation, single-nucleus RNA sequencing, and protein validation, the authors implicate D2-MSN hyperactivation and PKC overactivation as contributors to restricted and repetitive behavior.
-
Sodium Citrate in Translational SERS Research
2026-10-05
Sodium citrate is more than a familiar buffer or anticoagulant reagent: its chelation and pH-control properties may become important variables in biologically relevant SERS workflows. This thought-leadership article interprets a recent 3D gold nanocluster study, defines the evidence boundaries, and outlines how translational researchers can evaluate chemical context without confusing product specifications with assay validation.
-
Prestained Protein Marker F4005: Product Overview
2026-10-05
A concise, supplier-described overview of APExBIO’s EDTA-free Triple color protein ladder spanning 10–250 kDa, with no matched paper evidence available.
-
MAPK10–KRT16 Axis in NSCLC Metastasis
2026-10-04
The reference study proposes a phosphorylation-dependent mechanism in which MAPK10 marks KRT16 for RNF213-mediated ubiquitination and proteasomal degradation, thereby restraining NSCLC cell migration and invasion. Cellular, animal, and clinical observations support the MAPK10–KRT16–RNF213 axis as a promising research framework, although its prognostic and therapeutic relevance still requires broader validation.
-
CCT007093: Evidence, Mechanism, and Limits
2026-10-03
A source-grounded overview of CCT007093 as a research PPM1D inhibitor, examining its proposed relationship with p38 MAPK signaling, pyroptosis, and cancer-cell viability while separating reported findings from interpretation and identifying key evidence gaps.
-
Forsythoside E and the PKM2–Macrophage Axis
2026-10-02
A translational framework for using Forsythoside E to connect PKM2 state, macrophage metabolism, STAT3 signaling, and sepsis-induced liver injury research.
-
CD28–ARS2–PKM2 Control of CD8+ T-Cell Metabolism
2026-10-01
This 2024 study identifies ARS2-dependent alternative splicing as a previously underappreciated mechanism linking CD28 costimulation to metabolic flexibility in CD8+ T cells. The findings show that CD28–ARS2 signaling favors PKM2 over PKM1, supporting glucose utilization, interferon-γ production, and antitumor effector activity independently of canonical PI3K signaling.
-
PAD4-IN-2 TFA: An Assay-First Research Guide
2026-10-01
PAD4-IN-2 TFA, also known as Compound 5i TFA, offers a tumor-targeted way to investigate PAD4, histone H3 citrullination, and NET biology. This assay-first guide explains how to separate tumor-cell uptake, migration effects, neutrophil responses, and translational safety signals.
-
TPA: ERK/MAPK and PKC Signaling Tool
2026-09-30
12-O-tetradecanoyl phorbol-13-acetate (TPA) is a protein kinase C activator used to stimulate ERK/MAPK signaling in biochemical and cellular studies. Its value is highest in controlled pathway experiments and skin cancer models, where timing, solvent, storage, and pathway-specific controls determine interpretation.
-
HMGCS2, LysoPC, and Pulmonary Fibrosis
2026-09-30
Yang et al. identify injured type II alveolar epithelial cells as a major source of accumulated lysophosphatidylcholines and define an HMGCS2–PPARα–CPT1A/CPT2 axis that links epithelial lipid dysregulation to fibroblast activation. The study provides a mechanistic framework for lipid signaling pathway analysis in pulmonary fibrosis and supports epithelial lipid metabolism as a potential intervention point.